This article is for informational purposes only. It summarizes preclinical literature on BPC-157 (Body Protection Compound-157), a synthetic pentadecapeptide studied exclusively in animal models, in vitro systems, and ex vivo tissue preparations. Nothing below is a medical recommendation. BPC-157 is sold by MOG Research for laboratory research only — not for human or animal administration.

---

Key Takeaways

• BPC-157 is a synthetic 15-amino-acid peptide (sequence: GEPPPGKPADDAGLV) derived from a partial sequence of a protein isolated from human gastric juice. CAS Number: 137525-51-0. Molecular formula: C62H98N16O22. Molecular weight: 1419.5 g/mol.
• In preclinical models, BPC-157 has been studied for its association with angiogenic signaling, particularly upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and endothelial nitric oxide synthase (eNOS) expression.
• Animal studies have observed BPC-157’s influence on the nitric oxide (NO) system, dopaminergic and serotonergic signaling, and growth hormone receptor expression in rodent tissues.
• The most extensively documented research area is gastrointestinal cytoprotection — the original framework from which BPC-157 was derived in the 1990s.
• Research-grade BPC-157 is typically supplied as a lyophilized powder at ≥99% purity, HPLC and mass spectrometry verified, and stored at -20°C protected from light.

---

What Is BPC-157?

BPC-157 — “Body Protection Compound-157” — is a synthetic pentadecapeptide composed of 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It corresponds to a partial sequence isolated from a larger 40-kDa protein originally identified in human gastric juice. The compound was first characterized in the early 1990s by the laboratory of Predrag Sikiric at the University of Zagreb, where it has been the subject of the longest sustained preclinical research program of any peptide in this class.

Structurally, BPC-157 is unusual among synthetic peptides for its high stability in aqueous solution at physiological pH. Reported half-life data in rodent gastric environments has shown the molecule resisting enzymatic degradation that destabilizes comparable peptides within minutes, a characteristic that has supported its frequent use in oral-administration animal studies in addition to parenteral routes.

For laboratory work, BPC-157 is conventionally supplied as a lyophilized (freeze-dried) white powder. Reconstitution is typically performed using bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection, dependent on the specific research protocol. Once reconstituted, peptide solutions are kept at 2–8°C and used within 28–30 days to minimize degradation.

---

Why “Mechanism of Action” Is a Complicated Question for BPC-157

Unlike a small-molecule drug that engages a single defined receptor, BPC-157 does not have one widely accepted primary target. Decades of preclinical work have instead identified a constellation of signaling pathways that the peptide appears to influence concurrently. Researchers have proposed that BPC-157 functions as a pleiotropic modulator — a compound that adjusts multiple parallel systems toward a homeostatic baseline rather than activating one receptor.

This characterization matters for the reader of mechanistic studies: BPC-157 papers rarely report a single dose-response curve at a defined target. They instead describe broad shifts in tissue gene expression, vascular density, and growth-factor staining. The mechanistic story is mosaic, not monolithic. With that framing, the sections below summarize the most-documented signaling observations from the published literature.

---

1. Angiogenesis and VEGFR2 Signaling

Among the most reproducible findings in BPC-157 preclinical research is the association between the peptide and upregulation of angiogenic signaling — the formation of new blood vessels from existing vasculature.

In a 2018 study by Hsieh et al. published in the Journal of Molecular Medicine, BPC-157 administration in a rat ischemia model was associated with increased expression of VEGFR2 (vascular endothelial growth factor receptor 2) in vascular endothelial cells and with measurable increases in microvascular density in tissues adjacent to ischemic injury sites. (PMID: 27094611)

Subsequent work — Chang et al. (2014), published in Vascular Pharmacology — examined the peptide’s effect on endothelial tube formation in vitro using human umbilical vein endothelial cells (HUVECs). Treated cells exhibited accelerated tube-network formation compared to controls, an effect that was attenuated in the presence of VEGFR2 inhibitors. This pattern was interpreted by the authors as suggesting that BPC-157’s angiogenic signal is at least partially mediated through the VEGFR2 axis. (PMID: 24837557)

These observations have made the VEGFR2 pathway the most-cited mechanistic anchor in BPC-157 literature, although the exact molecular event upstream of VEGFR2 activation — whether direct binding, indirect ligand modulation, or transcriptional change — has not been conclusively resolved in published work.

---

2. The Nitric Oxide System

A second signaling system that recurs across BPC-157 research is the nitric oxide (NO) pathway. Multiple rodent studies, principally from the Sikiric laboratory, have reported that BPC-157 administration modulates expression of endothelial nitric oxide synthase (eNOS) and influences NO-mediated vasodilation.

A 2016 review by Sikiric et al. in Current Pharmaceutical Design compiled data from multiple rodent models in which BPC-157 was administered in the context of NO-system perturbation (using L-NAME, a NOS inhibitor, or L-arginine, an NO substrate). Across these models, BPC-157 was reported to counteract both NO depletion and NO overproduction — an effect the authors framed as evidence of NO-system “homeostatic adjustment” rather than directional activation. (PMID: 26314873)

The downstream implications of this NO interaction, in preclinical models, include observations of altered blood flow in injured tissues and altered platelet function in vascular injury preparations. The interpretation of these findings remains the subject of ongoing research and should not be extrapolated to human pharmacology.

---

3. Growth Hormone Receptor Expression

Chang et al. (2011), publishing in the Journal of Applied Physiology, examined BPC-157 in a rat Achilles tendon transection model. The researchers reported that peptide administration was associated with upregulation of growth hormone receptor (GHR) expression in tendon fibroblasts, alongside increased fibroblast proliferation in the regenerating tendon tissue. (PMID: 21030672)

The proposed framework — speculative but consistent across follow-up studies — is that BPC-157 may sensitize peripheral tissues to circulating growth hormone by increasing local receptor density. This is distinct from elevating systemic growth hormone levels (which BPC-157 has not been reported to do in rodent serum analyses). The functional consequence in tendon repair models was accelerated collagen organization and increased tensile strength of the regenerating tissue compared to vehicle-treated controls.

These tendon findings have made BPC-157 a frequent target compound in musculoskeletal regeneration research, though the relevance of rodent tendon healing data to other species or other tissue types is a matter for further preclinical investigation.

---

4. Gastrointestinal Cytoprotection

BPC-157’s research origin is gastrointestinal. The parent protein from which the 15-amino-acid sequence was derived was first isolated for its protective effect against experimentally induced gastric lesions in rat models. The earliest published BPC-157 work — Sikiric et al., 1993 and 1997 — documented prevention and accelerated resolution of gastric ulcers induced by alcohol, NSAIDs, and stress conditions in rodents. (PMID: 9678616)

Mechanistically, the gastrointestinal protection effects observed in these models have been associated with:

• Maintenance of mucosal integrity under chemical insult
• Modulation of prostaglandin synthesis pathways
• Influence on the gut–brain axis through dopaminergic and serotonergic signaling
• Preservation of vascular integrity in the submucosal vascular bed (linking back to the angiogenesis/NO findings above)

A 2014 study by Klicek et al. in Inflammopharmacology examined BPC-157 in a rat colitis model induced by dextran sulfate sodium (DSS). The peptide was associated with reduced histological evidence of mucosal disruption and reduced expression of inflammatory markers in colonic tissue. (PMID: 24500571)

This body of work represents the longest-running and most internally consistent line of preclinical BPC-157 research.

---

5. Dopaminergic and Serotonergic Signaling

A smaller but distinct cluster of BPC-157 preclinical research examines the peptide’s interaction with central neurotransmitter systems — particularly dopaminergic and serotonergic signaling in rodent brain regions.

A 2017 study by Sikiric et al. published in Inflammopharmacology reported that BPC-157 administration counteracted both haloperidol-induced (dopamine antagonist) catalepsy and L-DOPA-induced gait disturbances in rat models. The bidirectional counteraction was again interpreted as evidence of homeostatic, rather than directional, signaling at the dopaminergic system. (PMID: 28735378)

Serotonin synthesis enzymes have likewise been reported to shift in rodent brain tissue following BPC-157 administration. The relevance of these neurochemical observations to broader systemic effects is a question that remains open in the literature.

---

6. Musculoskeletal and Soft Tissue Repair

Beyond tendon, a series of preclinical studies have examined BPC-157 in muscle, ligament, and bone injury models. Krivic et al. (2008), publishing in the Journal of Orthopaedic Research, reported accelerated healing of transected medial collateral ligaments in rats following systemic BPC-157 administration, with measurable improvements in load-to-failure testing of the recovered ligament. (PMID: 18288714)

The interpreted mechanism in these soft-tissue models — across multiple authors — has been the convergence of:

• Increased local angiogenesis (VEGFR2 pathway)
• Increased growth factor receptor density (GHR pathway)
• Fibroblast proliferation and collagen reorganization
• Reduced inflammatory marker expression at the injury site

These mechanisms in combination have produced the modest, consistent “accelerated healing” finding that recurs across BPC-157 musculoskeletal research papers.

A 2010 paper by Sikiric et al. extended the soft-tissue findings to acutely transected rat skeletal muscle, reporting earlier appearance of organized myofiber regeneration and reduced fibrotic scar deposition in BPC-157-treated animals compared to saline controls. The histological pattern observed — fibroblast infiltration followed by orderly collagen deposition rather than disorganized scar formation — has been interpreted as supportive of a coordinated regenerative signaling profile rather than a single pro-proliferative effect. (PMID: 20925288)

Importantly, the methodological limitations of this body of work are widely acknowledged in the literature: most BPC-157 musculoskeletal studies use small rodent samples, single-laboratory replication, and varied dose regimens that complicate cross-study comparison. Researchers designing new BPC-157 protocols are encouraged to consult the original papers for full methodological context rather than relying on review summaries alone.

---

Summary of Documented Signaling Pathways

Pathway	Direction of Reported Effect	Primary Models
VEGFR2 / angiogenesis	Upregulation in injured tissue	Rat ischemia, HUVEC tube formation
eNOS / nitric oxide	Bidirectional homeostatic adjustment	Rat NO-system perturbation models
Growth hormone receptor	Upregulation in fibroblasts	Rat Achilles tendon transection
Gastrointestinal mucosa	Mucosal protection / repair	Rat alcohol, NSAID, stress, DSS-colitis models
Dopaminergic	Bidirectional homeostatic adjustment	Rat haloperidol/L-DOPA models
Serotonergic	Modulation of biosynthesis enzymes	Rodent brain tissue analysis

This table summarizes recurring findings across the cited literature. Direction-of-effect descriptors apply to the specific preclinical model from which they were reported and should not be generalized.

---

Reconstitution, Storage, and Handling for Researchers

For laboratories working with BPC-157, the operational considerations that influence experimental reproducibility include:

• Storage of lyophilized peptide: -20°C, protected from light and moisture. Stability at -20°C is typically reported through 24–36 months from manufacture.
• Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) is the conventional solvent for multi-use vials in animal protocols; sterile water for injection is used for single-use preparations. Gentle swirling of the vial after solvent addition is preferred over vortexing or shaking, which can mechanically disrupt the peptide.
• Reconstituted storage: 2–8°C, used within 28–30 days. Avoid repeated freeze-thaw cycles, which degrade peptide integrity progressively with each cycle.
• Verification: A Certificate of Analysis (COA) accompanying each lot should report HPLC purity ≥99%, mass spectrometry confirmation of molecular weight, and endotoxin testing (LAL) below the standard threshold for research-grade material.

MOG Research provides batch-specific COAs with every order of BPC-157, HPLC and mass spectrometry verified, lyophilized at ≥99% purity, with batch number and testing date printed on each vial.

---

Frequently Asked Questions

What is BPC-157’s mechanism of action in one sentence?

BPC-157 is a pleiotropic pentadecapeptide that has been observed in preclinical models to modulate angiogenic signaling (via VEGFR2), the nitric oxide system, growth hormone receptor expression in peripheral tissue, and dopaminergic/serotonergic neurotransmission, without a single confirmed primary receptor target.

Has BPC-157 been studied in humans?

As of May 2026, BPC-157 has not been approved for human therapeutic use by the FDA or comparable regulatory agencies. The published literature on BPC-157 is overwhelmingly preclinical: rodent studies, in vitro cell systems, and ex vivo tissue preparations. Any references to human application are outside the scope of established research.

Is BPC-157 the same as TB-500?

No. BPC-157 (15 amino acids, derived from gastric juice protein) and TB-500 (a synthetic fragment of Thymosin Beta-4, a 43-amino-acid protein) are distinct compounds with distinct sequences, structures, and reported preclinical signaling profiles. They are sometimes examined in combination in animal models because of their theorized complementary roles — BPC-157 acting more locally, TB-500 distributing more systemically — but the molecules themselves are not interchangeable. See our BPC-157 vs TB-500 comparison guide for a side-by-side review.

What purity standard should research-grade BPC-157 meet?

The accepted research-grade minimum is ≥99% purity verified by HPLC, with molecular identity confirmed by mass spectrometry, and endotoxin levels below the standard LAL threshold. A Certificate of Analysis documenting all three metrics should accompany each batch. For background on how to read a COA, see our peptide quality standards guide.

How is research-grade BPC-157 stored?

Lyophilized BPC-157 is stored at -20°C in a standard laboratory freezer, sealed and protected from light. Stability under these conditions is typically reported through 24–36 months. Once reconstituted in bacteriostatic water, the solution is kept at 2–8°C and used within 28–30 days, avoiding repeated freeze-thaw cycles.

---

Citations

The studies referenced in this article are listed below in chronological order. All citations link to PubMed.

• Sikiric P et al. (1997). Pharmacological properties of the novel peptide BPC 157. (PMID: 9678616)
• Krivic A et al. (2008). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. (PMID: 18288714)
• Chang C-H et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. (PMID: 21030672)
• Klicek R et al. (2014). Stable gastric pentadecapeptide BPC 157 in colitis. (PMID: 24500571)
• Chang C-H et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. (PMID: 24837557)
• Sikiric P et al. (2016). Stable gastric pentadecapeptide BPC 157 and the NO-system review. (PMID: 26314873)
• Hsieh M-J et al. (2018). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and signaling. (PMID: 27094611)
• Sikiric P et al. (2017). Stable gastric pentadecapeptide BPC 157 and the central nervous system. (PMID: 28735378)

---

Continue Reading

• BPC-157 vs TB-500: Two Distinct Signaling Pathways Examined in Preclinical Research
• How to Read a Peptide Certificate of Analysis
• Peptide Reconstitution Guide: BAC Water Ratios and Technique
• Product page: BPC-157 ≥99% Purity, HPLC Verified

---

BPC-157 is sold by MOG Research for laboratory and scientific research purposes only. This product is not intended for human or animal consumption. It is not a drug, is not FDA approved, and is not for therapeutic use. All references to research findings in this article describe published preclinical work and do not constitute medical advice, dosing recommendations, or health claims. Qualified researchers operating in compliant laboratory environments are the intended audience for this material.

This article is for informational purposes only. It is written for qualified researchers and laboratory purchasers evaluating replacement suppliers for research-grade peptides following the closure of Peptide Sciences in March 2026. It does not constitute medical, legal, or financial advice. All compounds referenced are sold by MOG Research strictly for laboratory research use — not for human or animal administration.

---

TL;DR

• Peptide Sciences (peptidesciences.com) ceased operations in early March 2026, ending what had been the largest US-facing research peptide supplier by traffic and order volume.
• Researchers who relied on Peptide Sciences for BPC-157, TB-500, GHK-Cu, MT-2, Epitalon, and Retatrutide are now sourcing from a fragmented post-shutdown landscape.
• This guide outlines what to evaluate in a replacement supplier — purity verification, batch-specific COAs, US-based fulfillment, and compliant RUO framing — and identifies MOG Research as one option that carries Peptide Sciences’ top five compounds with HPLC + MS-verified purity at ≥99%.

---

What Happened to Peptide Sciences

Peptide Sciences operated as a US-facing research peptide supplier from approximately 2013 through early 2026. Public web archive data and industry coverage place the formal cessation of operations on or around March 6, 2026, when the company’s storefront stopped processing new orders and the catalog was removed. Order fulfillment for outstanding shipments was reported to have continued for several weeks afterward before the customer support channels also went dark.

The reasons for the shutdown have not been publicly stated by the company. Industry observers have pointed to the broader 2025–2026 regulatory environment — including FDA enforcement activity against several other gray-market peptide vendors during the same period — as part of the context, but no official statement from Peptide Sciences has confirmed any specific trigger.

At the time of shutdown, third-party analytics estimated Peptide Sciences at roughly 990,000 monthly site visits. That volume of researchers, lab purchasers, and individual buyers is now distributed across a smaller number of remaining suppliers, none of which inherited the customer base cleanly. The resulting market is more fragmented than it was in 2025, and more researchers are spending time vetting unfamiliar vendors than at any point in the recent history of the niche.

---

Why This Matters for Researchers

For laboratory programs that built standard operating procedures around a single supplier’s lot numbers, COA formats, and reconstitution protocols, a sudden vendor disappearance is a real operational disruption. Replacing a vendor is not just placing an order with someone new — it involves re-validating purity profiles, updating internal documentation, and in some cases revising study protocols to account for any source-related variability in batch-to-batch peptide identity.

The post-Peptide Sciences market has three notable characteristics that affect supplier selection:

1. Surge in low-quality entrants. New peptide storefronts appeared rapidly during March–May 2026 attempting to capture displaced demand. Many of these operate without verifiable third-party testing.
2. Reputational pressure on incumbents. Vendors that did not receive FDA scrutiny in 2025–2026 are now seeing increased order volume, which has stressed the fulfillment and quality control systems of some operators.
3. Confusion about regulatory framing. Researchers are encountering inconsistent “research use only” disclaimers, conflicting purity claims, and varying levels of COA transparency across the remaining vendor pool.

A careful evaluation framework is more important now than it was in 2025.

---

What to Look for in a Replacement Supplier

The criteria below are the operational checks experienced laboratory purchasers apply when onboarding a new research peptide vendor. None of these are unique to MOG Research or to peptides — they are the same standards applied to any research chemical procurement.

1. HPLC Purity Verification at ≥99%

High-Performance Liquid Chromatography (HPLC) is the standard analytical method for confirming peptide purity. Research-grade material should report ≥99% purity by HPLC. Numbers below 98% indicate either lower-grade material or batch variability that is unsuitable for sensitive research applications.

2. Mass Spectrometry Confirmation of Identity

Purity alone does not confirm molecular identity. Mass spectrometry (MS) — typically reported alongside HPLC on the Certificate of Analysis — confirms that the peptide synthesized matches the expected molecular weight for the target sequence. A COA listing only HPLC purity without an MS trace is incomplete.

3. Batch-Specific COA Per Lot

A single “company-wide” COA file is a red flag. Each manufacturing lot produces a distinct peptide sample with its own purity profile, endotoxin reading, and testing date. Reputable suppliers issue a unique COA per batch and link that batch number to the specific vial(s) shipped to the researcher. The COA should be downloadable or accessible by lot number.

4. Endotoxin Testing (LAL)

For applications involving cell culture, in vivo work, or any preparation where bacterial endotoxin contamination would compromise results, the COA should include LAL (Limulus Amebocyte Lysate) endotoxin testing below the standard research-grade threshold. This is a less universally reported metric, but its presence on a COA is a signal of higher manufacturing standards.

5. US-Based Fulfillment

Domestic manufacturing and shipping reduce transit time, eliminate customs holds, and provide a clearer chain of custody. Suppliers that warehouse and ship from inside the United States typically deliver within 2–4 business days and avoid the freeze-thaw cycles associated with international shipping delays.

6. Reasonable, Transparent Pricing

Pricing significantly below the market median is often a leading indicator of either substandard material or unsustainable operations that will exit the market quickly. Pricing significantly above market without corresponding documentation of additional testing or purity is not justified. Reasonable suppliers price BPC-157 5mg in the $35–$50 range, BPC-157 10mg in the $60–$80 range, and GHK-Cu 50mg in the $40–$60 range as of mid-2026.

7. Compliant RUO Framing

The vendor’s site language matters. Suppliers that imply human dosing, suggest therapeutic outcomes, or use clinical language are signaling either regulatory naivety or willingness to operate outside the RUO framework. Both are risks. Compliant vendors use research-context language throughout and place visible “Research Use Only” disclaimers on every product page.

8. Functional Customer Support and Documentation

Replying within one business day, responding to COA requests, and providing handling and storage documentation are basic operational signals. A supplier whose support email bounces or whose contact form does not generate a reply is not a supplier you can rely on for reorders during an active research program.

---

MOG Research as a Replacement Option

MOG Research is a US-based research peptide supplier operating from domestic manufacturing and fulfillment. The catalog currently includes the five compounds most frequently sourced from Peptide Sciences prior to its closure: BPC-157, TB-500, GHK-Cu, Melanotan II (MT-2), and Retatrutide. Each is supplied as a lyophilized powder, ≥99% HPLC-verified purity, with a batch-specific Certificate of Analysis available per lot.

Operational standards:

• Purity: ≥99% HPLC verified, mass spectrometry confirmed
• Endotoxin: LAL tested per batch, below standard research-grade threshold
• Storage at fulfillment: -20°C cold-chain through ship-out
• Shipping: Same-day fulfillment for orders placed before 2:00 PM ET; 2–4 business day USPS Priority delivery within the United States
• COA access: Batch-specific PDF linked from each product page and printed with each order
• Support: Email reply within one business day at office@mogresearch.com

MOG Research is not making a claim to be a 1-for-1 replacement for any prior supplier. The position offered here is that the catalog overlap, purity standards, and operational profile make MOG Research a viable evaluation candidate for researchers who relied on Peptide Sciences’ BPC-157, TB-500, GHK-Cu, MT-2, or Retatrutide.

---

Compound-by-Compound Replacement Guide

The five most-ordered compounds at Peptide Sciences (based on independent third-party traffic analysis of category pages prior to shutdown) and their direct equivalents in the MOG Research catalog:

BPC-157

A 15-amino-acid synthetic peptide (sequence: GEPPPGKPADDAGLV; CAS: 137525-51-0; MW: 1419.5 g/mol) extensively studied in preclinical models for angiogenic signaling, nitric oxide modulation, and gastrointestinal cytoprotection. Available from MOG Research in 5mg and 10mg lyophilized vials. See the BPC-157 product page and the BPC-157 mechanism of action review.

TB-500

A synthetic fragment of Thymosin Beta-4 (full TB-4 CAS: 77591-33-4) studied in preclinical literature for actin regulation and systemic tissue repair signaling. Available in 5mg and 10mg lyophilized vials. See the TB-500 product page.

GHK-Cu

A copper-bound tripeptide (Glycine-Histidine-Lysine + Cu²⁺; CAS: 49557-75-7) studied in preclinical models for collagen synthesis signaling, fibroblast activation, and extracellular matrix research. Available in 50mg and 100mg lyophilized vials. See the GHK-Cu product page.

Melanotan II (MT-2)

A cyclic heptapeptide analogue of α-melanocyte stimulating hormone (α-MSH; CAS: 121062-08-6) studied for melanocortin receptor agonism in preclinical pigmentation research. Available in 10mg lyophilized vials. See the MT-2 product page.

Retatrutide

A novel triple agonist (LY3437943) of the GLP-1, GIP, and glucagon receptors, studied in preclinical metabolic research. Available in 10mg and 20mg lyophilized vials. See the Retatrutide product page.

---

What MOG Research Does Not Currently Carry

For transparency, the following compounds that were available at Peptide Sciences are not part of the current MOG Research catalog: Epitalon, Sermorelin, MOTS-C, Humanin, Selank, Semax, and several less-common compounds. Researchers who require these compounds in the same order as the five listed above may need to source from multiple suppliers in the near term. MOG Research catalog expansion is under active evaluation based on researcher demand; questions or compound requests can be directed to office@mogresearch.com.

---

Frequently Asked Questions

When did Peptide Sciences shut down?

Peptide Sciences ceased accepting new orders on or around March 6, 2026. The storefront catalog was removed shortly afterward, and customer support channels went unresponsive over the following weeks.

Has Peptide Sciences reopened or relocated?

As of May 19, 2026, there is no public indication that Peptide Sciences has resumed operations under the original brand or relocated to a new domain. Researchers should be cautious of new sites claiming to be the “official” continuation — none have been publicly confirmed.

Is MOG Research’s BPC-157 the same as Peptide Sciences’ BPC-157?

BPC-157 is the same molecule regardless of supplier — a synthetic pentadecapeptide with sequence GEPPPGKPADDAGLV. Sourcing the same compound from a different manufacturer means working with a different batch, a different COA, and potentially a different purity profile at the margins. MOG Research’s BPC-157 is supplied at ≥99% HPLC-verified purity with batch-specific COA, which is the same standard Peptide Sciences claimed on its product pages.

Can I trust the COAs from a new supplier?

A COA from a reputable laboratory will include the testing facility’s name, the testing date, the batch number, the analytical methods used, and the specific results. If any of those four fields are absent — or if the COA is unsigned and undated — verify directly with the supplier before placing a research order. MOG Research COAs include all four fields.

Are there other reputable peptide suppliers besides MOG Research?

Yes. The remaining post-Peptide Sciences vendor landscape includes several established US-based suppliers. Researchers should apply the same evaluation criteria to any vendor under consideration — purity verification, batch-specific COAs, US fulfillment, RUO framing, and operational responsiveness. This article is not a claim that MOG Research is the only option, only that it is a viable one for the catalog overlap described above.

---

Continue Reading

• BPC-157 Mechanism of Action: What Current Preclinical Research Shows
• How to Read a Peptide Certificate of Analysis
• Peptide Reconstitution Guide: BAC Water Ratios and Technique
• Research Peptide Quality Standards

---

All compounds discussed in this article are sold by MOG Research for laboratory and scientific research purposes only. They are not intended for human or animal consumption, are not drugs, are not FDA approved, and are not for therapeutic use. References to other suppliers in this article are based on publicly available information and are provided for informational comparison only; no endorsement or affiliation is implied. Qualified researchers operating in compliant laboratory environments are the intended audience for this material.